Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Qur Medical Aps currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, CLARK, AMY LYNN, who operates within 1 distinct art unit. The prosecution activity is centralized, as this 1 pending action accounts for the entire current workload for the portfolio. Practitioners should note that the company's immediate patent office interactions are limited to this specific examiner and art unit.
The busiest examiner for the portfolio is CLARK, AMY LYNN, who is responsible for 1 pending office action. Because there is only 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy does not require coordination across multiple divisions. This concentration suggests a patent portfolio where all active matters are consolidated under a single point of review at the patent office. The presence of 1 pending office action indicates a prosecution pipeline that is currently limited to a single matter. This allows for a response strategy tailored to the specific requirements of the 1 distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARK, AMY LYNN | 1 | 39.2% | +31.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554391 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED DISEASE | CLARK, AMY LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554391 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED DISEASE | CLARK, AMY LYNN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554391 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED DISEASE | CLARK, AMY LYNN | 1628 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQur Medical Aps has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amy Lynn Clark has the most, with 1 of Qur Medical Aps's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
